Home / Market News / $RVMD
benzinga Corporate Catalyst Impact 75/100 ● positive

Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow

Oct 16, 2026, 5:08 PM UTC · Primary ticker $RVMD

William Blair initiated coverage on Revolution Medicines with an Outperform rating and a $226 price target, citing significant growth opportunities beyond pancreatic cancer. This positive analyst coverage follows recent FDA approval and European backing for their lead drug, Rasonque, and highlights the potential of their RAS(ON) inhibitor pipeline.

William Blair initiated coverage on Revolution Medicines (RVMD) with an Outperform rating and a $226 price target, a significant vote of confidence for the biotechnology company. This positive outlook is driven by the recent FDA approval and European recommendation for Rasonque in pancreatic cancer, and the analyst's belief in the broader potential of RVMD's RAS(ON) inhibitor pipeline. This news is a short-term positive catalyst for RVMD, potentially driving further stock appreciation. Long-term implications depend on the successful expansion of their drugs into other cancer types and the outcomes of ongoing clinical trials, offering both significant opportunity and risk.

$RVMD positive Positive analyst coverage and strong drug pipeline
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.